Investigating the Efficacy, Safety and PK of Roxadustat (FG-4592) for Treatment of Anemia in Pediatric Patients With CKD

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

May 23, 2022

Primary Completion Date

May 23, 2022

Study Completion Date

May 23, 2022

Conditions
Anemia Associated With Chronic Kidney Disease
Interventions
DRUG

Roxadustat

HIF-PH inhibitor for treatment of anemia in CKD

Trial Locations (4)

10029

Icahn School of Medicine at Mount Sinai (ISMMS) - The Mount Sinai Hospital (MSH), New York

60611

Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago

68198

University of Nebraska Medical Center, Omaha

78215

Investigative site, San Antonio

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

FibroGen

INDUSTRY